Atlas Health Venture - Bridging Healthcare Innovation. Connecting Global Opportunity.

Health Innovation Is an Investment Segment That Matters

The Atlas Healthcare Innovation Ecosystem

Market Size

A Global Healthcare Market Heading to $15tn

$

11tn

currently spent on healthcare globally, expected to reach $15tn by 2030

15 to 25%

expected growth of the global digital health market, reaching more than $1,250bn by 2030

1.6bn

projected global 65+ population by 2050, roughly double today level

~75%

of deaths worldwide caused by non-communicable diseases

Source: World Bank, Statista, World Economic Forum, World Health Organisation; Grand View Research, Artificial Intelligence In Healthcare Market 2026.

BURDEN OF DISEASE

The Burden of Disease Affects the Economy and Wellbeing Globally

Epidemiological shift towards chronic diseases

Non-communicable diseases such as diabetes, cardiovascular diseases and cancer now account for the vast majority of the global healthcare burden. Regions such as the GCC exhibit some of the highest prevalence rates globally, particularly in diabetes and obesity.

Ageing populations increase system pressure

Rapid demographic shifts are driving sustained growth in chronic disease prevalence. Older populations require continuous care, monitoring and advanced therapeutic solutions.

Healthcare systems under stress seeking health-tech solutions

Healthcare systems face unsustainable cost and capacity pressures, creating strong demand for scalable, technology-enabled solutions across prevention and early detection, chronic disease management and care delivery optimisation.

The Burden of Disease Affects the Economy and Wellbeing Globally
Healthcare Startup Funding and AI Deal Momentum

EMERGING MARKET GAPS
Addressed by Our Platform

  • Difficulties in achieving robust clinical validation, and local regulators eager to support innovation but lacking structured frameworks for execution.
  • Heavy reliance on imported technology, devices and pharmaceuticals, and limited R&D ecosystems.
  • HealthTech companies selling into highly fragmented ecosystems, facing friction on compliance, reimbursement and scaling into international healthcare markets.
  • An emerging venture capital pool that is well capitalised through sovereigns and family offices but lacks healthcare expertise and proactive sourcing.